Workflow
三生国健: 三生国健:2024年年度股东大会会议资料
688336Sunshine Guojian Pharmaceutical(688336) 证券之星·2025-04-03 10:11

Core Viewpoint - The company is preparing for its 2024 annual general meeting, outlining the procedures and agenda for the meeting, including various proposals for shareholder approval [1][2][3]. Meeting Procedures - The meeting will ensure the presence of relevant stakeholders, including shareholders, directors, supervisors, and invited guests, while excluding unrelated personnel [1][2]. - Shareholders must register and present necessary documentation to participate in the voting process, with late arrivals not permitted to vote [2][3]. - The meeting will follow a predetermined agenda for discussing and voting on proposals [2][3]. Proposals for Approval - Proposal 1: The board's work report for 2024 has been prepared and submitted for shareholder review [5]. - Proposal 2: The financial settlement report for 2024 has been created and is ready for approval [5]. - Proposal 3: The financial budget report for 2025 has been prepared for shareholder consideration [6]. - Proposal 4: The annual report for 2024 is submitted for approval [6]. - Proposal 5: The reappointment of Ernst & Young Hua Ming as the auditing firm for 2025 is proposed [7]. - Proposal 6: A profit distribution plan for 2024 is proposed, with a cash dividend of RMB 0.90 per share [8][9]. - Proposal 7: The remuneration plan for directors in 2025 is outlined, with independent directors receiving RMB 100,000 annually [10]. - Proposal 8: The execution of related party transactions for 2024 and projections for 2025 are presented, ensuring compliance with regulations and fair pricing [11][21]. Financial Performance - The company reported a net profit of RMB 704.58 million for 2024, with an unallocated profit of RMB 2.28 billion as of December 31, 2024 [25]. - The total revenue for 2024 was RMB 1.19 billion, reflecting a stable growth trajectory [25]. - The company’s operating costs increased to RMB 304.34 million, a rise of 35.80% compared to the previous year, primarily due to increased sales volumes [25]. Governance and Compliance - The board of directors has adhered to legal requirements and company regulations in conducting meetings and decision-making processes [27][28]. - The company has established a robust internal control system to enhance governance and risk management [31].